SCHEMBL27250643

SCHEMBL27250643

COc1ncc(Br)cc1N1CCN(C(C)(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.36
CNR2 P34972 1/20 0.34
METAP1 P53582 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
GFER P55789 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
OPRK1 P41145 2/20 0.31
PIK3CD O00329 1/20 0.31
PIK3R1 P27986 1/20 0.31
HRH4 Q9H3N8 2/20 0.30
HRH3 Q9Y5N1 1/20 0.30
PIK3CA P42336 1/20 0.30
MTOR P42345 1/20 0.30
SSTR4 P31391 1/20 0.30
RAF1 P04049 1/20 0.30
BRAF P15056 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31000957 1.00 HTR1A (0.36) HTR1ACNR2METAP1CHRNB2CHRNA4
SCHEMBL27250826 0.83 ATR (0.37) METAP1LMNAL3MBTL1PIK3CDPIK3R1
SCHEMBL30925338 0.83 ATR (0.37) METAP1LMNAL3MBTL1PIK3CDPIK3R1
SCHEMBL27250827 0.80 PIK3CD (0.31) LMNAL3MBTL1PIK3CDRAF1BRAF
SCHEMBL29182674 0.79 KMT2A (0.41) GFERKMT2ALMNAHRH4HRH3
SCHEMBL16036128 0.79 CCR5 (0.44) KMT2AOPRK1PIK3CDPIK3CAMTOR
SCHEMBL30930985 0.79 KMT2A (0.41) GFERKMT2ALMNAHRH4HRH3
SCHEMBL30931083 0.79 ATR (0.35) CNR2METAP1CHRNB2CHRNA4LMNA
SCHEMBL29182874 0.76 HRH4 (0.32) HRH4HRH3
SCHEMBL29182741 0.76 HTR1A (0.31) HTR1AMETAP1HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. 2024-07-04 US disclosed
WO-2024123999-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. (US) 2024-06-13 WO disclosed
WO-2024124000-A1 TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. (US) 2024-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN BRDT, BET1, BRD4 HTR1A 4020/4885CNR2 3185/4885METAP1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.